Dengue fever is a significant public health concern, particularly in tropical and subtropical regions. The disease is transmitted by Aedes mosquitoes and can lead to severe complications such as dengue hemorrhagic fever and dengue shock syndrome. The development of Dengvaxia represents a major advancement in the control and prevention of dengue outbreaks. It has the potential to reduce the incidence of dengue and thereby decrease the burden on healthcare systems.
